Patents by Inventor Cecelia C. Yates-Binder
Cecelia C. Yates-Binder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918625Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.Type: GrantFiled: April 20, 2022Date of Patent: March 5, 2024Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes
-
Publication number: 20220257718Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C—X—C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.Type: ApplicationFiled: April 20, 2022Publication date: August 18, 2022Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes
-
Patent number: 11406687Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: September 18, 2020Date of Patent: August 9, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 11338017Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.Type: GrantFiled: March 29, 2019Date of Patent: May 24, 2022Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes
-
Publication number: 20210000919Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 10561710Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: GrantFiled: January 9, 2018Date of Patent: February 18, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20190298802Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C—X—C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.Type: ApplicationFiled: March 29, 2019Publication date: October 3, 2019Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Tuskegee University, The University of North Carolina at Chapel Hill, The United States of America as represented by the Department of Veterans AffairsInventors: Cecelia C. Yates-Binder, Jesse Jaynes, Monte S. Willis, Richard J. Bodnar, Zariel I. Johnson
-
Publication number: 20180333460Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: ApplicationFiled: January 9, 2018Publication date: November 22, 2018Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20180280478Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: December 19, 2017Publication date: October 4, 2018Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9895419Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: GrantFiled: January 20, 2015Date of Patent: February 20, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Patent number: 9872889Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 24, 2016Date of Patent: January 23, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20170000852Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: ApplicationFiled: January 20, 2015Publication date: January 5, 2017Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20160361387Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: August 24, 2016Publication date: December 15, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9452200Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: October 8, 2015Date of Patent: September 27, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20160022779Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: October 8, 2015Publication date: January 28, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9180167Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3(CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10), or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 23, 2012Date of Patent: November 10, 2015Assignee: University of Pittsburgh-Of The Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20140178451Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.Type: ApplicationFiled: August 23, 2012Publication date: June 26, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 8734775Abstract: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the ?-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.Type: GrantFiled: August 26, 2011Date of Patent: May 27, 2014Assignees: University of Pittsburgh, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes, Timothy Turner, Alan Wells, Richard J. Bodnar
-
Publication number: 20130053319Abstract: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the ?-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Inventors: Cecelia C. Yates-Binder, Jesse Jaynes, Timothy Turner, Alan Wells, Richard J. Bodnar